High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Malignant Glioma
Interventions
DRUG

Irinotecan (Camptosar, CPT-11)

"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."

Trial Locations (1)

40202

Kentuckiana Cancer Institute, Louisville

All Listed Sponsors
lead

Kentuckiana Cancer Institute

OTHER

NCT00283556 - High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma | Biotech Hunter | Biotech Hunter